Table 1.
Identification of Final Study Population
| Sequential attrition | Patients remaining,a N (%) |
|---|---|
| Index diagnosis date between January 1, 2010, and June 30, 2012 | 5399 (41.9) |
| Continuous eligibility between 1-year preindex and 2 years postindex | 2182 (16.9) |
| Aged ≥18 years at index diagnosis date | 2135 (16.6) |
| No exclusionary diagnosis during the 3-year patient-specific study time frame | 1063 (8.2) |
| No treatment of interest in the 12-month preindex period (ie, IVIG, corticosteroid, immunosuppressant, plasma exchange) | 879 (6.8) |
| Total population of treated patients, plus untreated patients with a second diagnosis of CIDP within >90 days of index diagnosis of CIDP | 525 (4.1) |
| Final sample size | 525 (4.1) |
a
Number of patients remaining after each exclusion.
CIDP indicates chronic inflammatory demyelinating polyneuropathy; IVIG, intravenous immunoglobulin.